2023
Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey
Harsono D, Deng Y, Chung S, Barakat L, Friedland G, Villanueva M, Yager J, Justen M, Edelman E. Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey. AIDS And Behavior 2023, 28: 1531-1545. PMID: 37824037, PMCID: PMC11349050, DOI: 10.1007/s10461-023-04170-5.Peer-Reviewed Original ResearchPhysical activity guidelinesPhysical inactivityPhysical activityDetectable HIV viral loadSelf-reported physical activitySample of PWHHIV viral loadPhysical activity levelsUnhealthy alcohol useFirst COVID-19 waveImproved health outcomesCross-sectional surveyHIV clinicCOVID-19 waveActivity guidelinesAdjusted analysisCOVID-19 transmissionViral loadTobacco useCoping strategiesSedentary lifestyleLower oddsPsychological coping strategiesHealth outcomesDisease controlThe Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-EngagementImplementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut
Wegener M, Brooks R, Speers S, Nichols L, Villanueva M. Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut. Public Health Reports 2023, 139: 208-217. PMID: 37232422, PMCID: PMC10851907, DOI: 10.1177/00333549231172173.Peer-Reviewed Original ResearchHIV viral loadHCV coinfectionViral loadSurveillance databaseUndetectable HIV viral loadDetectable HIV viral loadDisease controlHIV/AIDS Reporting SystemHCV elimination strategyRecent HIV testAIDS Reporting SystemElectronic Disease Surveillance SystemOutcomes of peoplePublic health departmentsDisease surveillance systemsSurveillance-based approachHCV cureHCV statusHepatitis CAntiviral medicationsHIV testC virusViral testingHealth departmentsInitial infection
2022
Advancing data to care strategies for persons with HIV using an innovative reconciliation process
Villanueva M, Miceli J, Speers S, Nichols L, Carroll C, Jenkins H, Altice F. Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLOS ONE 2022, 17: e0267903. PMID: 35511958, PMCID: PMC9071117, DOI: 10.1371/journal.pone.0267903.Peer-Reviewed Original ResearchConceptsDisease intervention specialistsHIV care continuumCare continuumNon-randomized patientsPublic health surveillance dataOngoing HIV transmissionClinic visit dataHealth surveillance dataPublic health surveillanceHIV clinicHIV eliminationViral loadHIV transmissionCare engagementCopies/Clinic staffClinic dataYale University SchoolVisit dataHealth surveillancePWHSurveillance dataPatientsCells/Intervention specialists
2021
The Cooperative Re-Engagement Controlled trial (CoRECT): A randomised trial to assess a collaborative data to care model to improve HIV care continuum outcomes
Fanfair R, Khalil G, Williams T, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled trial (CoRECT): A randomised trial to assess a collaborative data to care model to improve HIV care continuum outcomes. The Lancet Regional Health - Americas 2021, 3: 100057. PMID: 36777404, PMCID: PMC9903939, DOI: 10.1016/j.lana.2021.100057.Peer-Reviewed Original ResearchActive public health interventionMonths of randomizationViral load suppressionHIV viral loadPublic health interventionsViral loadCD4 countViral suppressionCare participantsCare strategiesHealth departmentsHealth interventionsDays of randomizationProportion of PWHStandard of careNon-Hispanic blacksHIV careContinuum outcomesHIV infectionMedian timeHIV transmissionCopies/Group overallClinic dataMedical careNational Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR, Piquant D, Link K, Hemmersbach-Miller M, Pearson T, Turgeon N, Lyon G, Kitchens W, Huckaby J, Lasseter A, Elbein R, Roberson A, Ferry E, Klock E, Cochran W, Morrison M, Rasmussen S, Bollinger J, Sugarman J, Smith A, Thomas M, Coakley M, Timpone J, Stucke A, Haydel B, Dieter R, Klein E, Neumann H, Gallon L, Goudy L, Callegari M, Marrazzo I, Jackson T, Pruett T, Farnsworth M, Locke J, Mompoint-Williams D, Basinger K, Mekeel K, Nguyen P, Kwan J, Srisengfa T, Chin-Hong P, Rogers R, Simkins J, Munoz C, Dunn T, Sawinski D, Silveira F, Hughes K, Pakstis D, Nagy J, Baldecchi M, Muthukumar T, Eddie M, Robb K, Salsgiver E, Witting B, Azar M, Villanueva M, Formica R, Tomlin R. National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases 2021, 74: 2010-2019. PMID: 34453519, PMCID: PMC9187316, DOI: 10.1093/cid/ciab743.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistance mutationsHIV-positive donorsHIV drug resistance mutationsViral loadMedian CD4 T-cell countCD4 T-cell percentagesHIV Organ Policy Equity (HOPE) ActCD4 T-cell countNonnucleoside reverse transcriptase inhibitorIntegrase strand transfer inhibitorsDonor-derived infectionInhibitor-based regimensT cell percentageT-cell countsHepatitis C viremiaHIV viral loadCD4 T cellsDeceased organ donorsReverse transcriptase inhibitorFalse-positive test resultsStrand transfer inhibitorsC viremiaVirologic characteristicsClinical characteristics
2020
543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19
Virata M, Villanueva M, Shenoi S, Ladines-Lim J, Aoun-Barakat L. 543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19. Open Forum Infectious Diseases 2020, 7: s338-s338. PMCID: PMC7777445, DOI: 10.1093/ofid/ofaa439.737.Peer-Reviewed Original ResearchSARS-CoV-2 viral loadViral loadRespiratory samplesViral dynamicsUndetectable HIV viral loadSARS-CoV-2 infectionSevere acute respiratory syndrome 2SARS-CoV-2 viral dynamicsMedian CD4 countRetrospective cohort studyCells/mm3HIV viral loadRNA viral loadMain outcome measuresUrban academic centerCT of patientsPresentation of illnessYears of ageCOVID-19SARS-CoV-2COVID-19 diseaseCycle threshold valuesHospital mortalityAdvanced diseaseCD4 count
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection